AbbVie (NYSE: ABBV) has officially closed its $10.9 billion acquisition of Apogee Therapeutics (NASDAQ: APGE), a move that promises long-term rewards but demands near-term patience. The company forecasts that the deal will not add to adjusted earnings until 2032, a six-year timeline that underscores the speculative nature of the investment.
The transaction, announced in June, is expected to reduce AbbVie's adjusted earnings by $0.46 per share in 2027, following a $0.14 per share impact in 2026. This near-term drag is a deliberate trade-off as AbbVie bets on Apogee's lead candidate, zumilokibart, for atopic dermatitis, a chronic inflammatory skin condition.
Market Reaction and Stock Performance
Investors have shown measured optimism. AbbVie shares closed Friday at $256.46, down 1.4% for the session, but still 18.5% above their June 18 close, the last trading day before the deal became public. The market's muted response reflects the long wait for returns, with the company's core immunology franchise—Skyrizi and Rinvoq—expected to fund the interim period.
CEO Robert Michael called the completion "an important step in further strengthening AbbVie's leadership in immunology and advancing our long-term growth strategy." The company reaffirmed its 2026 adjusted EPS guidance of $13.87 to $14.07.
Immunology Engine Powers the Gamble
AbbVie's existing immunology portfolio is performing strongly. In the second quarter, immunology revenue rose 15.1% year-over-year to $8.79 billion. Skyrizi generated $5.51 billion, up 24.4%, while Rinvoq contributed $2.53 billion, a 24.5% increase. Humira, once the company's flagship, declined 35.9% to $756 million, but the growth of the newer drugs is more than compensating.
This momentum is crucial because Apogee has no approved products. Zumilokibart is entering Phase 3 trials for atopic dermatitis, and its potential hinges on successful trials and regulatory approval. The Phase 2 data showed 65.9% of patients on the mid-dose achieved EASI-75 at week 16, versus 23.4% for placebo, but these are cross-trial comparisons, not head-to-head tests.
Deal Financing and Clinical Risks
The purchase price was $135.11 per share in cash, valuing the deal at $10.1 billion net of acquired cash. AbbVie financed the acquisition with debt, including a $10 billion 364-day term loan. At the end of June, AbbVie had $6.57 billion in cash and $70.82 billion in debt, with plans to reduce net leverage to two times within two to three years.
Clinical and regulatory risks remain. Apogee reported a net loss of $85.9 million in the June quarter and spent $67.3 million on R&D. Any delays in Phase 3 enrollment or regulatory setbacks could push the 2032 payoff further out. Analysts like William Blair's Matt Phipps note that the acquisition allows AbbVie to accelerate Phase 3 development and potentially reduce royalty obligations to Blackstone.
For now, AbbVie's stock suggests shareholders are willing to wait, but the operating business must deliver consistent growth to justify the patience.
